Fourth-generation Vaping Devices Increase Risk to Immune Cells

Innovation
Jul.01.2022
With the FDA ordering Juul to stop selling their e-cigarette devices, UNC School of Medicine researchers led by Ilona Jaspers, PhD, published the first study to compare the respiratory immune health effects of different types of devices.

CHAPEL HILL, NC – Not all electronic cigarette devices are created equal. Some fourth-generation models – such as Juul devices – are associated with unique changes in markers of immune responses inside our airways, according to a new peer-reviewed paper from UNC School of Medicine researchers led by toxicologist Ilona Jaspers, PhD, director of the UNC Center for Environmental Medicine, Asthma, and Lung Biology and director of the UNC Curriculum in Toxicology and Environmental Medicine.

 

Fourth-generation Vaping Devices Increase Risk to Immune Cells
Ilona Jaspers, PhD

 

Lead author Elise Hickman, PhD, a recent graduate from Jaspers’ lab, and colleagues, who published their research in the American Journal of Respiratory and Critical Care Medicine, found that users of fourth-generation nicotine-salt-containing devices display a unique mix of cellular biomarkers indicative of immune suppression.

 

“Our work demonstrates the importance of considering device type in future clinical, epidemiological, and mechanistic studies on the health effects of e-cigarettes,” said Jaspers, professor of pediatrics and microbiology and immunology. “We also think this research can help regulators determine which products cause the most severe types of biological changes in airway cells important for maintaining proper health.”

 

Electronic cigarettes have increased in popularity over the past decade. Some people began using them as a means to quit smoking, thinking vaping was a safer alternative, both in the short-term and long-term. Also, because electronic cigarettes lack tar, consumers assumed vaping decreased their risk of cancer down the road.

 

“It’s impossible to know if vaping decreases cancer risk or many other long-term conditions,” Jaspers said. “It took 60 years of research to show that smoking causes cancer.” E-cigarettes have been around for about 15 years. “Still, the research from our lab and many others has shown many of the same acute biological effects in the airways that we have documented in smokers,” she said. “And we’ve seen some changes to cells and immune defenses in people who vape that, frankly, we’ve never seen before, which is very concerning.”

 

Most concerning to researchers, doctors, and public health officials is the fact that teenagers who would not have otherwise tried cigarettes began using e-cigarettes, which contain nicotine – a drug with its own health implications even beyond addiction – and thousands of chemicals, many of which the FDA approved for eating but not inhaling.

 

Several studies have documented that inhaling chemical-laden nicotine aerosols suppresses the immune responses in the respiratory tracts of smokers and e-cigarette users. Some studies, including some at UNC, have detailed how different chemicals in various e-cigarettes, including chemicals that make up thousands of different flavors, have adverse effects on airway cells. The Jaspers lab, which has been at the forefront of such research, set out to study the effects of different varieties of e-cigarette devices. For this study, her team collected central airway (sputum) samples from non-smokers, smokers, and users of both third-generation and fourth-generation e-cigarette devices.

 

Third-generation devices include vape pens and box mods. Fourth generation include nicotine-salt-containing e-cigarettes, such as Juul products, and disposable e-cigarettes, which have become increasingly popular following restrictions on the sale of Juul products.

 

Fourth-generation e-cigarette users had significantly more bronchial epithelial cells in their sputum, and this suggests airway injury because normally, bronchial epithelial cells make up an intact barrier in the airways and are not found in sputum samples. Levels of two proteins, sICAM1 and sVCAM1, were significantly lower in fourth-generation e-cigarette users compared to all other groups. These proteins are important in fighting infections and other disease.

 

Also, proteins CRP, IFN-g, MCP-1, uteroglobin, MMP-2, and VEGF were significantly lower in fourth versus third generation e-cigarette users, and all of these proteins are important for overall immune defense. So, the more diminished these proteins are, the more suppressed our immune systems are. “Another key finding of the study was that, when examining the mixture of immune markers overall rather than one by one, fourth generation e-cigarette users had the most distinguishable changes out of all of the groups, indicating a shift away from immune homeostasis,” said Hickman.

 

This research does not reveal evidence that e-cigarettes cause cancer, emphysema, COPD, or other long-term diseases associated with long-term cigarette smoking. But researchers think that altering immune responses in the respiratory tract over the course of many years, especially for teens, could play a major role in the development of long-term health conditions and in susceptibility to inhaled pathogens.

 

The National Institutes of Health funded this research.

 

Elise Hickman, who earned an Impact Award from the UNC Graduate School, is the first author of the paper, and Ilona Jaspers is the senior author. Other authors are Alexis Payton, Parker Duffney, Heather Wells, Agathe S. Ceppe, Stephanie Brocke, Aleah Bailey, Meghan E. Rebuli, Carole Robinette, Brian Ring, Julia E. Rager, and Neil E. Alexis.

 

Also read:

FDA Denies Authorization to Market JUUL Products

 

Product | GEEKBAR Launches HOOKAH X on Its Official Website, Featuring Stepless DTL “Infinite Control”
Product | GEEKBAR Launches HOOKAH X on Its Official Website, Featuring Stepless DTL “Infinite Control”
GEEKBAR has launched the disposable hookah-style e-cigarette HOOKAH X on its official website. According to the product page, the device claims to feature “Stepless/Infinite Control,” enabling continuous adjustment across different airflow and draw-resistance ranges. HOOKAH X has also begun selling through online channels in the U.S., with pricing around US$21.99.
Dec.08 by 2FIRSTS.ai
BAT Taps McLaren Title Win for Travel Retail Activation, Launches VELO “Champions’ Edition” Nicotine Pouches
BAT Taps McLaren Title Win for Travel Retail Activation, Launches VELO “Champions’ Edition” Nicotine Pouches
British American Tobacco (BAT) is leveraging McLaren F1 Team’s 2025 Constructors’ Championship win to roll out a VELO×McLaren brand activation across the travel retail market. The campaign spans major airports in Abu Dhabi, the UK, Ireland and Spain, alongside the launch of a VELO “Champions’ Edition” product.
Dec.15 by 2FIRSTS.ai
China Opens 2026 National E-Cigarette Standards Project for Public Submissions
China Opens 2026 National E-Cigarette Standards Project for Public Submissions
The State Administration for Market Regulation (SAMR) and the State Tobacco Monopoly Administration (STMA) jointly announced the launch of the 2026 National Standardization Project for E-cigarettes. The initiative, coordinated by the National Technical Committee on Standardization of E-cigarettes, aims to enhance the industry’s regulatory framework through new standards on manufacturing, storage, distribution, and evaluation.
Nov.27 by 2FIRSTS.ai
84% of Britons Back Regulation of Nicotine Pouches, Survey Finds
84% of Britons Back Regulation of Nicotine Pouches, Survey Finds
A Northerner survey finds 84% of Britons support regulating nicotine pouches and 82% back a licensing scheme for vape sales, aligning with the Tobacco and Vapes Bill to improve consumer safety and youth protection.
Nov.06 by 2FIRSTS.ai
$200 Million Investment to Advance Smokeless Product Manufacturing at Reynolds
$200 Million Investment to Advance Smokeless Product Manufacturing at Reynolds
Reynolds American Inc. announced it will create 200 new manufacturing positions in 2026 at its Tobaccoville, North Carolina, Operations Center, bringing total new roles added over the past two years to more than 1,000. The company added 800 jobs between 2024 and 2025. These roles will support the continued growth of Velo Plus nicotine pouches and Reynolds’ expanding multi-category portfolio, aligned with its mission to build a smokeless world.
Dec.11 by 2FIRSTS.ai
HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia
HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia
HSSP INTL(03626.HK) partners with COTY to establish e-cigarette venture in UAE, expand distribution of Heaven Gifts brand.
Oct.30 by 2FIRSTS.ai